320 related articles for article (PubMed ID: 25796678)
21. Beclomethasone dipropionate (3 mg) enemas combined with oral 5-ASA (2.4 g) in the treatment of ulcerative colitis not responsive to oral 5-ASA alone.
D'Arienzo A; Manguso F; Castiglione GN; Vicinanza G; Scaglione G; Bennato R; Sanges M; Mazzacca G
Ital J Gastroenterol Hepatol; 1998 Jun; 30(3):254-7. PubMed ID: 9759590
[TBL] [Abstract][Full Text] [Related]
22. Curcumin for Inflammatory Bowel Disease: A Caution.
Holt PR
Clin Gastroenterol Hepatol; 2016 Jan; 14(1):168. PubMed ID: 26343179
[No Abstract] [Full Text] [Related]
23. Mesalamine (5-aminosalicylic acid) therapy well tolerated in a patient with aspirin hypersensitivity and ulcerative colitis.
Murphy SJ; Mayer L; Abreu MT
J Clin Gastroenterol; 2011 Jan; 45(1):83-4. PubMed ID: 20535023
[No Abstract] [Full Text] [Related]
24. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?
Riley SA
Gut; 1998 Jun; 42(6):761-3. PubMed ID: 9691909
[No Abstract] [Full Text] [Related]
25. Mesalamine with MMX technology for the treatment of ulcerative colitis.
Schreiber S; Kamm MA; Lichtenstein GR
Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):299-314. PubMed ID: 19072380
[TBL] [Abstract][Full Text] [Related]
26. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.
Eliakim R; Tulassay Z; Kupcinskas L; Adamonis K; Pokrotnieks J; Bar-Meir S; Lavy A; Mueller R; Greinwald R; Chermesh I; Gross V;
Aliment Pharmacol Ther; 2007 Nov; 26(9):1237-49. PubMed ID: 17944738
[TBL] [Abstract][Full Text] [Related]
27. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.
Harris MS; Lichtenstein GR
Aliment Pharmacol Ther; 2011 May; 33(9):996-1009. PubMed ID: 21385194
[TBL] [Abstract][Full Text] [Related]
28. [Ulcerative colitis. Complementary therapies].
Matthes H; Moser G; Jantschek G
Z Gastroenterol; 2004 Sep; 42(9):1031-2. PubMed ID: 15455282
[No Abstract] [Full Text] [Related]
29. Oral 5-aminosalicylic acid therapy for mild-to-moderate ulcerative colitis.
Olmstead J
J Am Acad Nurse Pract; 2010 Nov; 22(11):586-92. PubMed ID: 21054632
[TBL] [Abstract][Full Text] [Related]
30. Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis.
Piodi LP; Ulivieri FM; Cermesoni L; Cesana BM
Scand J Gastroenterol; 2004 Feb; 39(2):154-7. PubMed ID: 15000277
[TBL] [Abstract][Full Text] [Related]
31. Ulcerative colitis occurring in the course of rheumatoid arthritis: a case successfully treated with mesalamine enema.
Sugisaki K; Honma F; Iwadate H; Shio K; Shioya Y; Fukaya E; Sato K; Saito H; Sekine H; Kobayashi H; Orikasa H; Watanabe H; Sato Y
Intern Med; 2004 Nov; 43(11):1046-50. PubMed ID: 15609700
[TBL] [Abstract][Full Text] [Related]
32. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
Sandborn WJ
Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
[TBL] [Abstract][Full Text] [Related]
33. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
[TBL] [Abstract][Full Text] [Related]
34. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis.
Sandborn WJ
Am J Gastroenterol; 2002 Dec; 97(12):2939-41. PubMed ID: 12492172
[No Abstract] [Full Text] [Related]
35. [Ulcerative colitis and thrombocytopenia: a clinical case of fortuitous association?].
Braucci S; Trappolini F; Angrisani L; Luberti E; Clarice A; Proietta M; Pisani D; Trappolini M
Clin Ter; 2007; 158(1):27-30. PubMed ID: 17405657
[TBL] [Abstract][Full Text] [Related]
36. Reply.
Salomon N; Lang A; Ben-Horin S
Clin Gastroenterol Hepatol; 2016 Jan; 14(1):168. PubMed ID: 26432475
[No Abstract] [Full Text] [Related]
37. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
Moum B
Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043
[TBL] [Abstract][Full Text] [Related]
38. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
[TBL] [Abstract][Full Text] [Related]
39. Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile.
Danese S; Bonovas S; Peyrin-Biroulet L
J Crohns Colitis; 2017 Jul; 11(7):767-768. PubMed ID: 28333203
[No Abstract] [Full Text] [Related]
40. [Mesalazine in ulcerative colitis. Fewer cases of colorectal carcinoma].
MMW Fortschr Med; 2002 Feb; 144(9):51. PubMed ID: 11921656
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
